CervoMed (US:CRVO) ZACKS·2026-03-13 23:15分组1 - CervoMed Inc. reported a quarterly loss of $0.88 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.79, and compared to a loss of $0.80 per share a year ago, indicating an earnings surprise of -10.93% [1] - The company posted revenues of $0.01 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 98.06%, and down from $2.16 million in the same quarter last year [2] - CervoMed Inc. shares have declined approximately 45.2% since the beginning of the year, contrasting with the S&P 500's decline of 2.5% [3] 分组2 - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The estimate revisions trend for CervoMed Inc. was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold), suggesting the shares are expected to perform in line with the market in the near future [6] - The current consensus EPS estimate for the upcoming quarter is -$0.88 on revenues of $0.55 million, and for the current fiscal year, it is -$2.33 on revenues of $2.7 million [7] 分组3 - The Medical - Biomedical and Genetics industry, to which CervoMed Inc. belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, indicating that the industry's outlook can significantly impact stock performance [8]